PetCure Oncology says it has now treated 10,000 patients

PetCure Oncology says it has crossed a major utilization milestone: 10,000 patients treated with radiation therapy. In a January 7, 2026 announcement, the company positioned the benchmark as more than a marketing moment, arguing it reflects a structural change in veterinary oncology, where stereotactic radiation therapy is no longer confined mainly to academic institutions and a handful of geographies. PetCure, part of the Thrive Pet Healthcare ecosystem, has spent the last decade building a referral-based network aimed at making advanced radiation oncology more available in specialty practice settings. (petcureoncology.com)

That framing tracks with the company’s own historical data. In its 2017 report on its first roughly 1,100 patients, PetCure described a market where radiation access was still limited, noting that conventional fractionated radiation often required 15 to 21 weekday treatments, each involving anesthesia for veterinary patients. The same report outlined the company’s early pitch for stereotactic radiosurgery and stereotactic radiation therapy: highly conformal treatment, fewer acute side effects in many cases, and one to three treatment sessions for selected tumors. PetCure also emphasized from the beginning that it wanted to aggregate outcomes data across a national network and support referring veterinarians with remote specialist input. (petcureoncology.com)

The company’s newer milestone messaging suggests that model has scaled. PetCure said in April 2024 that it had treated 8,000 pets, and that announcement tied the growth to Thrive Pet Healthcare’s national reach and to PetCure’s board-certified radiation oncology services. Current public-facing materials indicate PetCure has treatment locations across multiple U.S. markets, while the Veterinary Cancer Society’s 2024 radiation facilities list shows PetCure-branded radiation sites embedded in specialty hospitals in places including Campbell, California, and other regional hubs. A separate PetCure location page also highlights a newer Chicago-area site inside Thrive Pet Healthcare Specialists in Hoffman Estates, Illinois. (petcureoncology.com)

PetCure’s recent commentary also points to where it thinks the field is heading next. In a 2025 trends piece, chief medical officer Neal Mauldin highlighted mobile radiation therapy as an emerging direction, while a November 2025 partnership announcement said Thrive and Empyrean Medical Systems plan to bring the Sirius advanced radiation platform to a Seattle-area PetCure site in early 2026. dvm360, covering that announcement, quoted Mauldin calling the technology “a major leap forward” for delivering precise, noninvasive treatment with minimal adverse effects. That planned launch suggests PetCure is pairing its access narrative with a technology-upgrade narrative as competition in specialty oncology intensifies. (petcureoncology.com)

Independent expert reaction specific to the 10,000-patient milestone was limited in public sources, but the broader industry context supports the significance of expanded access. The Veterinary Cancer Society’s facility listings still show radiation oncology as a relatively concentrated service line, especially compared with general specialty care. PetCure’s own materials have long argued that the bottleneck is not just technology, but geography, protocol complexity, and the difficulty primary care veterinarians face when referral options are distant or fragmented. That argument is self-interested, coming from the company itself, but it aligns with the practical reality many clinicians see in oncology referrals. (vetcancersociety.org)

Why it matters: For veterinary professionals, this milestone is best understood as a signal about infrastructure, not just case volume. Radiation oncology remains a niche, capital-intensive service, and access still depends heavily on regional availability, specialist staffing, imaging, anesthesia support, and pet parent finances. If private networks like PetCure and Thrive continue to widen the referral map, more general practitioners and medical oncologists may be able to present radiation earlier as a realistic option rather than a theoretical one. That could influence case triage, client counseling, and expectations around multimodal cancer care, especially for tumors where shorter stereotactic courses may reduce repeated anesthesia exposure and travel burden. At the same time, clinicians will still need to separate broad access claims from patient-specific appropriateness, because not every tumor, stage, or pet is a candidate for SRS or SRT. (petcureoncology.com)

What to watch: The next marker will be whether PetCure turns this volume milestone into measurable clinical evidence, new published outcomes, or further expansion, especially as its Seattle launch and newer market entries test whether advanced radiation therapy can keep moving closer to where pet parents and referring veterinarians actually are. (empyreanmed.com)